These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series. Datta S; Singh S; Govindarajan R J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555 [TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Howard JF; Barohn RJ; Cutter GR; Freimer M; Juel VC; Mozaffar T; Mellion ML; Benatar MG; Farrugia ME; Wang JJ; Malhotra SS; Kissel JT; Muscle Nerve; 2013 Jul; 48(1):76-84. PubMed ID: 23512355 [TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis: the role of complement at the neuromuscular junction. Howard JF Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249 [TBL] [Abstract][Full Text] [Related]
11. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Mantegazza R; O'Brien FL; Yountz M; Howard JF; Ann Clin Transl Neurol; 2020 Aug; 7(8):1327-1339. PubMed ID: 32700461 [TBL] [Abstract][Full Text] [Related]
12. Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series. Levine TD Am J Case Rep; 2019 Jul; 20():965-970. PubMed ID: 31278249 [TBL] [Abstract][Full Text] [Related]
13. Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review. Waheed W; Newman E; Aboukhatwa M; Moin M; Tandan R Ther Clin Risk Manag; 2022; 18():699-719. PubMed ID: 35855752 [TBL] [Abstract][Full Text] [Related]
14. Myasthenia gravis with achalasia secondary to thymoma: a case report and literature review. Haridy NA; Khedr EM; Hasan AM; Maghraby AA; Abdelmohsen E; Aly AM Egypt J Neurol Psychiatr Neurosurg; 2023; 59(1):34. PubMed ID: 36936607 [TBL] [Abstract][Full Text] [Related]
15. Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab. Mimori M; Komatsu T; Maku T; Mitsumura H; Iguchi Y Neurol Sci; 2022 Jul; 43(7):4081-4083. PubMed ID: 35364770 [TBL] [Abstract][Full Text] [Related]
17. Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report. Vu T; Harvey B; Suresh N; Farias J; Gooch C Case Rep Neurol; 2021; 13(1):65-72. PubMed ID: 33708096 [TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T; Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280 [TBL] [Abstract][Full Text] [Related]